Ionic Capital Management’s enGene Therapeutics Warrants ENGNW Stock Holding History

Ionic Capital Management’s Portfolio ENGNW Stock Details ENGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$42.4K	Buy	+16,753	New	+$49.6K	﹤0.01%	144

Other funds holding ENGNW

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Ionic Capital Management's ENGNW Position: Q1 2026 in Review

Ionic Capital Management opened a new position in enGene Therapeutics Warrants (ENGNW) in Q1 2026: 16,753 shares worth $42.4K. The stake represents ﹤0.01% of the portfolio and ranks #144 among its holdings.

11 funds tracked by Wall St. Rank hold ENGNW as of Q1 2026.

Ionic Capital Management held 16,753 shares of enGene Therapeutics Warrants worth $42.4K as of Q1 2026.
enGene Therapeutics Warrants was a new Ionic Capital Management position in Q1 2026.
enGene Therapeutics Warrants made up ﹤0.01% of Ionic Capital Management's portfolio in Q1 2026, its #144 holding.
11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q1 2026.

Based on Ionic Capital Management's 13F filing for Q1 2026, filed 15 May 2026.